Back to Search
Start Over
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals
- Publication Year :
- 2008
- Publisher :
- BENTHAM SCIENCE PUBL LTD, 2008.
-
Abstract
- (i) To compare early decrease of HIV plasma viral load (pVL) after two standard-combinations of highly active antiretroviral therapy (HAART) (ii) To evaluate variations of proviral HIV-DNA load on conditions of sustained pVL undetectability. Two different sub-studies of a multicentre prospective randomized controlled trial which compared two first-line HAART (i.e., zidovudine+lamivudine+lopinavir/ritonavir versus tenofovir+lamivudine+ efavirenz). Only patients enrolled at the coordinating centre (University of Brescia) were included in the two sub-studies. In the first sub-study, we calculated pVL decrease with respect to baseline at any of the following time-point: days 1, 3, 7, 14 and 28. Decreases of the pVL were compared between the two treatment groups. In the second sub-study, we'analyzed, variation of proviral HIV-DNA load in CD4+ T-cells from baseline to week 52 only in patients who maintained the same treatment regimen and had sustained undetectable pVL. In either studies, linear regression analysis was used to investigate what factors could influence variations of pVL and of proviral HIV-DNA load. (i) 64 patients were studied. A significant decrease of pVL was found from day 3 on, without statistically significant differences between the two study groups. However, after adjusting for possible confounders, tenofovir+lamivudine+efavirenz resulted to be associated with greater pVL decreases. (ii) 45 patients were studied. Mean proviral HIV-DNA load decreased from 1,610 (95%CI: 879-2,341) to 896 (95% CI 499-1,293) copies/106 cells (P=0.05). Linear regression analysis showed that the decrease of proviral DNA load during follow-up was independently and inversely correlated with age. Further studies are needed to compare pVL decay between antiretroviral regimens and assess whether proviral HIV-DNA load is a surrogate marker of treatment effectiveness. © 2008 Bentham Science Publishers Ltd.
- Subjects :
- CD4-Positive T-Lymphocytes
Cyclopropanes
Male
HAART
HIV Infections
Gastroenterology
law.invention
chemistry.chemical_compound
Randomized controlled trial
law
Antiretroviral Therapy, Highly Active
Organophosphonate
Medicine
HIV Infection
Alkyne
Plasma viral load
virus diseases
Lamivudine
Lopinavir
Cyclopropane
Middle Aged
Viral Load
Antiretroviral therapy
Reverse Transcriptase Inhibitor
Infectious Diseases
HIV
Treatment Outcome
CD4-Positive T-Lymphocyte
Alkynes
Reverse Transcriptase Inhibitors
Boosted protease inhibitors
Non nucleoside reverse transcriptase inhibitors
Proviral HIV-DNA
Female
Viral load
medicine.drug
Human
Adult
Benzoxazine
medicine.medical_specialty
Efavirenz
Boosted protease inhibitor
Organophosphonates
Non nucleoside reverse transcriptase inhibitor
Drug Administration Schedule
Zidovudine
Virology
Internal medicine
Humans
Tenofovir
Surrogate endpoint
business.industry
Adenine
Biomarker
Benzoxazines
CD4 Lymphocyte Count
chemistry
Immunology
DNA, Viral
HIV-1
Ritonavir
business
Biomarkers
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....f143f4fb5fd01fd590a3593cd4a0f704